Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $7,218,750.00 in Stock

Humacyte, Inc. (NASDAQ:HUMA – Get Rating) CEO Laura E. Niklason sold 2,625,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $2.75, for a total value of $7,218,750.00. Following the completion of the transaction, the chief executive officer now owns 15,365,736 shares in the company, valued at approximately $42,255,774. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Humacyte Stock Performance

NASDAQ HUMA traded up $0.09 on Friday, hitting $3.70. 376,419 shares of the company’s stock were exchanged, compared to its average volume of 252,662. The company has a debt-to-equity ratio of 0.42, a current ratio of 5.67 and a quick ratio of 5.67. The firm’s 50-day moving average price is $3.55 and its two-hundred day moving average price is $3.07. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $6.38. The firm has a market cap of $382.32 million, a price-to-earnings ratio of -12.33 and a beta of 1.22.

Analyst Upgrades and Downgrades

Separately, Benchmark reiterated a “buy” rating and set a $16.00 target price on shares of Humacyte in a research report on Monday, March 27th.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. boosted its stake in shares of Humacyte by 17.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 15,947 shares of the company’s stock worth $51,000 after acquiring an additional 2,347 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Humacyte by 24.7% during the 2nd quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock worth $55,000 after acquiring an additional 3,364 shares in the last quarter. Susquehanna International Group LLP boosted its stake in shares of Humacyte by 16.2% during the 1st quarter. Susquehanna International Group LLP now owns 31,367 shares of the company’s stock worth $97,000 after acquiring an additional 4,372 shares in the last quarter. UBS Group AG boosted its stake in shares of Humacyte by 92.0% during the 3rd quarter. UBS Group AG now owns 9,827 shares of the company’s stock worth $32,000 after acquiring an additional 4,710 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Humacyte by 24.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 25,020 shares of the company’s stock worth $177,000 after acquiring an additional 4,946 shares in the last quarter. Institutional investors and hedge funds own 13.05% of the company’s stock.

About Humacyte

(Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).